

43531

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gianfranco MERIZZI

Group Art Unit: N/A

Serial No.: NEW

Examiner: N/A

Filed: March 8, 2002

For: AN ANTIOXIDANT PREPARATION  
BASED ON PLANT EXTRACTS FOR THE  
TREATMENT OF CIRCULATION AND  
CHRONIC DEGENERATIVE PROBLEMS  
AND OF HYPERTENSION

INFORMATION DISCLOSURE STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. § 1.97 and § 1.98, Applicant brings the disclosures attached and listed on completed Form PTO-1449 to the Examiner's attention and requests that they be considered and made of record in this application.

Prompt examination on the merits is respectfully requested.

Respectfully submitted,

Dated: March 8, 2002



Lance G. Johnson  
Reg. No. 32,531

Roylance, Abrams, Berdo & Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W. – Suite 600  
Washington, D.C. 20036  
(202) 659-9076

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. 43531	SERIAL NO. <b>10/070656</b> NEW
APPLICANT Gianfranco MERIZZI		
FILING DATE March 8, 2002		GROUP N/A

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		YES	NO											
	WO	0	1	1	9	1	5	8	3/2001	Europe				
	GB	2	1	7	4	9	0	4	11/1986	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	Redox Report, vol. 5, Nos. 2-3, 2000, pages 144-145; <u>Body Contouring Using An Oral Herbal Antioxidant Formulation - Centelaplast: A Dose Controlled Observational Study</u> , Wayne Reilly and Vivienne Reeve (XP-000990069).

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.